Google
FDMT — 4D MOLECULAR THERAPEUTICS INC (Healthcare >> Biotechnology)
FDMT FAQ
What is FDMT's P/E ratio?
4D MOLECULAR THERAPEUTICS INC (FDMT) currently trades at a P/E ratio of 24.98.
What is FDMT's ROE?
4D MOLECULAR THERAPEUTICS INC reports a Return on Equity (ROE) of -35.61%.
What is FDMT's dividend yield?
4D MOLECULAR THERAPEUTICS INC offers a dividend yield of 0.00%.
What is FDMT's Deepscope Quality Score?
Deepscope rates FDMT's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy FDMT?
Deepscope's AI Timing Score for FDMT is 63 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does FDMT belong to?
4D MOLECULAR THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 9.53
Price
0.26
(2.80%)
Day Change
|
|
|---|
FDMT, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 9.53 |
| PBV / Sector |
1.07 / 4.48
GREAT
|
| Earning Per Share | -3.16 |
| PE / Sector |
24.98 / 16.68
|
| PEG or PE/Growth / Sector |
-3.62 / 0.53
|
| Average 1M Daily Value |
7.27 M
|
| Average 1W Daily Value |
12.20 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:10 |
| Symbol | FDMT |
| Name | 4D MOLECULAR THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 52.28 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 484.60 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5858 Horton Street, EmeryVille, CA, United States, 94608
Phone: 510 505 2680
Website: https://www.4dmoleculartherapeutics.com
Employees: 196
Sector: Healthcare >> Biotechnology
Description: 4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
